Race Oncology (ASX: RAC) has reached a key milestone, with the Southside Cancer Care Centre in Miranda, NSW, now activated for patient enrolment in its Phase 1 clinical trial of RC220 for advanced solid tumours.
Trial Overview
- Multi-site study: Conducted in Australia, Hong Kong, and South Korea.
- Combination therapy: Investigating RC220 with doxorubicin, a widely used chemotherapy drug.
- Key objectives:
- Assess safety, tolerability, and pharmacokinetics of RC220.
- Determine the maximum tolerated combined dose (MTCD) with doxorubicin.
- Evaluate cardioprotective and anticancer effects, focusing on m6A RNA biomarkers.
Trial Design & Potential Impact
The trial will recruit up to 33 patients for dose escalation, followed by 20 additional patients in an expansion phase. Using a Bayesian trial design, this approach enhances flexibility and speeds up the clinical process.
A meta-analysis by Race Oncology suggests that doxorubicin alone has up to a 35% response rate in various advanced cancers, including breast, lung, ovarian, bladder, and liver cancers. Preclinical data indicates that RC220 enhances doxorubicin’s cancer-killing effects in 85% of cancer cell lines tested.
Management Commentary
Race CEO Dr Daniel Tillett stated:
“I am proud of the hard work and dedication from the Race clinical team, George Clinical, and CCF in reaching this point. I look forward to soon treating the first patient with RC220 and advancing it as a potential new treatment that improves cancer therapy while protecting patients from serious side effects.”
Cancer Care Foundation CEO Dr Tony Noun added:
“This is another positive step in exploring the potential for RC220. Thank you to our Director of Clinical Trials, Dr Mahmood Alam, and the entire team for bringing this project to fruition.”
With patient enrolment now underway, Race Oncology moves closer to unlocking a promising new treatment option for cancer patients.
